Literature DB >> 33945544

Chinese consumers' willingness to get a COVID-19 vaccine and willingness to pay for it.

Wen Qin1, Erpeng Wang1, Zhengyu Ni1.   

Abstract

A COVID-19 vaccine is the key to beating the virus, and effective vaccines are going to be available in the near future. It is urgent to estimate the acceptability of COVID-19 vaccines and their value to individuals, in order to develop an effective public vaccination strategy. Based on a survey of 1,188 randomly selected respondents in China, we analyzed Chinese consumers' willingness to get a COVID-19 vaccine and their willingness to pay for it. We find that 79.41% of the respondents are willing to get vaccinated in China, and the average amount that they're willing to pay for a COVID-19 vaccine shot is 130.45 yuan. However, though the elderly are at higher risk of infection and the disease could be fatal for them, they are less willing to get the vaccine and not willing to pay as much for the shot. Subsidies and health communication concerning COVID-19 vaccines should be provided in order to expand vaccination coverage.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33945544      PMCID: PMC8096001          DOI: 10.1371/journal.pone.0250112

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

COVID-19, a serious respiratory illness, broke out in December 2019 and has quickly spread all over the whole world. The spread of the virus from person to person has been confirmed, and it has been found that the virus has higher transmissibility and is more likely to evolve into a pandemic than SARS-CoV [1]. By30 August 2020, more than 25 million cases of COVID-19 have been reported globally, with the U.S., Brazil and India leading the count, according to data from Johns Hopkins University [2]. The pandemic has led to severe global socioeconomic disruption and serious consumer stockpiling behavior [3]. By August 2020, no specific antiviral treatment has been proved effective [4]. For the general public, the best way of prevention is to wear masks and isolate themselves at home to avoid infection [5]. In this situation, multiple investments are made to conduct research into the development of COVID-19 vaccines which is the key to beating the virus. Although no vaccine has completed clinical trials, there are multiple attempts in progress. It is expected that effective vaccines would be available in the near future. While scientists around the world are rushing to create a COVID-19 vaccine, health communication experts say they need to start to lay the groundwork for acceptance now. Efficient investments in health protection require valid estimates of the public’s willingness to forgo consumption for diminished probabilities of disease [6]. The effectiveness of a vaccine also depends on the vaccination rate, because considering how contagious COVID-19 is, experts estimate that typically 70% to 90% of the population needs to be immune to achieve herd immunity [7]. Whether the public is willing to get vaccinated will determine whether they can reach herd immunity. In France, 26% of the respondents said they wouldn’t get a coronavirus vaccine, and a survey of 1,056 American people in mid-May showed that just 50% of Americans planned to get a COVID-19 vaccine [8]. Now there is little knowledge about vaccination behavior [9]. Few studies using contingent valuation surveys have estimated the willingness to pay for vaccines [9, 10]. Considering that differences across racial or ethnic groups may exacerbate racial or ethnic disparities in vaccination [11], it is important to understand Chinese people’s vaccination behavior in order to make an effective vaccination strategy. China’s immunization program has some characteristics that differ from those of other countries [12]. About 11 vaccines including those against hepatitis B and MMR (measles, mumps, rubella) are free for all children under 14 years of age, and these government-purchased vaccines are called Category 1 vaccines. In contrast, Category 2 vaccines, like the HPV vaccine and the flu vaccine, are paid by individuals. Take the flu vaccine for example. It is not currently included in the national Expanded Program on Immunization (EPI) in China. In Shanghai, a flu shot costs 53 to 136 yuan ($7 to $20) [13]. For the COVID-19 vaccine, there is still not a flat list price in China. Consumers in Wuhan need to pay 234 yuan ($35.83) for each shot, while it is free for high-risk groups at Guangdong, Zhejiang and Shandong provinces. The officials of China’s health departments claimed the vaccine price would depend on its scale of use and China will ensure the COVID-19 vaccines be affordable to all Chinese residents [14]. The objective of this study is to estimate the acceptability of a COVID-19 vaccine and its value to individuals, in order to develop an effective public vaccination strategy in China. Based on a survey of 1,188 randomly selected respondents in China, we estimate residents’ willingness to get vaccinated and their willingness to pay for a COVID-19 vaccine shot. Understanding consumers’ vaccination behavior could provide critical information for policy makers to help them identify possible barriers and develop strategies. This study also makes an important contribution to the few existing health economics studies on COVID-19 vaccination behavior.

Data collection

Sample

The online survey was conducted by a professional marketing research company (SO JUMP) from 11 to 13 March 2020 in China. Respondents all received daily briefings on novel coronavirus cases from March 10 to March 12. On March 10, 15 new cases of confirmed infections, 33 new cases of suspected infections, and 11 new deaths (10 in Hubei province) were reported on the Chinese mainland. During that time, the government locked down Wuhan and encouraged people to stay indoors to contain the spread of the virus. Around 42,600 health care professionals from all over China joined forces with the local medical workers to treat the patients and combating the epidemic [15]. Health care workers also provided residents with anti-epidemic preventive care, disinfection, publicity, and education. Through painstaking efforts and tremendous sacrifice, China has succeeded in controlling the spread of COVID-19. There were very few newly confirmed cases on the Chinese mainland between March 10 and March 12 (Fig 1), according to the white paper titled “Fighting COVID-19: China in Action”, which was issued by China’s State Council Information Office. The study was deemed exempt from requiring human subjects’ approval by the Institutional Review Board of Nanjing Tech University. The survey of this study contained no identifier items, such as name, address, etc. At the beginning of the questionnaire, we sought the consent of the participants. Only if they agreed, they would complete the questionnaire. And when filling out the questionnaire, they could skip any questions at any time. Our research does not involve any medical records or archived samples at all.
Fig 1

Daily figure of newly confirmed cases on the Chinese mainland [16].

Note: On February 12, newly confirmed cases reached 15,152 (including 13,332 cumulative clinically diagnosed cases in Hubei).

Daily figure of newly confirmed cases on the Chinese mainland [16].

Note: On February 12, newly confirmed cases reached 15,152 (including 13,332 cumulative clinically diagnosed cases in Hubei). Samples, randomly selected from a huge sample database (with 2.6 million samples), were from several representative provinces/cities. Hubei province, the epicenter of the coronavirus outbreak in China, is the most seriously affected. There were 67,781 cumulative cases of COVID-19 on March 10. Guangdong and Zhejiang provinces, with a large population, are the second worst pandemic-stricken regions, with 1,356 and 1,215 cumulative cases on March 10. Jiangsu, Hebei and Shaanxi provinces represent the areas with less risk of infection. Beijing is the political and cultural center of China. Shanghai is representative of global financial centers. The sample provinces/cities together account for 33.87% of the national population, and take 90% of all the cumulative cases on March 10 (there were 80,778 cumulative cases on March 10 in China). Table 1 reports their population and the daily figure of COVID-19 cases.
Table 1

The population and daily figure of COVID-19 cases in sample areas.

 PopulationProportion in the national populationNewly confirmed cases on March 10Newly confirmed cases on March 11Newly confirmed cases on March 12The cumulative cases on March 10
Hubei5,9274.23%85467,781
Guangdong11,5218.23%01(suspected case)01,356
Zhejiang5,8504.18%01(asymptomatic case)01,215
Jiangsu8,0705.76%000631
Beijing2,1541.54%010435
Shanghai2,4281.73%000344
Hebei7,5925.42%000318
Shaanxi3,8762.77%000245
Total47,41833.87%86472,325

Survey design

The survey was divided into three sections. The first part included questions about respondents’ characteristics, such as age, gender, monthly household income, educational level and perception of COVID-19 risk. The second part asked about consumers’ willingness to get a COVID-19 vaccine. Respondents were directly asked, “Do you plan to get a coronavirus vaccine when one is possible?” The third section was to elicit respondents’ willingness to pay for vaccines. Contingent valuation method (CVM) is one of popular stated preference methods to assess the value of nonmarket goods [17, 18]. CVM usually includes the continuous methods and the discrete method [19]. The payment card approach is one of the continuous methods of CVM, which is prevalent in the current literature [20-22]. Therefore, we used the payment card method to elicit respondents’ willingness to pay for vaccines. We asked respondents to assume that the price for a flu vaccine is 50 yuan when the mortality rate of flu is 0.1% [23], then requested them to pick the maximum acceptable price for a coronavirus vaccine if the mortality rate of COVID-19 is 0.4% [24]. Hence, we set the choices of price in the payment card to include 7 ranges: 50–75 yuan, 75–100 yuan, 100–125 yuan, 125–150 yuan, 150–200 yuan, 200–250 yuan, 250–300 yuan, and above 300 yuan.

Econometric model

A binary logit regression model was used to study the willingness to get vaccinated. If the respondent is willing, the dependent variable equals 1, and 0 if not. The binary logit regression model is the main technique to tackle such a data structure. Assuming that willingness to get vaccinated can be modeled as a linear function, Where y is whether willing to get vaccinated and X is a vector of demographic variables, ε is the random error. The interval regression was used to study the willingness to pay for vaccines, because the WTP from the payment card method consists of intervals and censoring observation. The interval regression is a generalized Tobit model [25], and the differences among censored, truncated, and interval data have been discussed by Cameron and Trivedi [26]. If the value for the jth individual is somewhere in the interval [y1, y2], the known boundaries of WTP, as well as the chosen range indicating the underlying maximum WTP for vaccination, are taken into the consideration of the interval-censored model. Since the interval data boundaries are already known, true WTP is assumed to locate in regions (−∞,y1),(y1,y2],…(y,∞). Assuming a latent variable WTP* indicates the true WTP by individual i:

Results and discussion

Willingness to get vaccinated

Removing the respondents with any missing responses, we collected 1,188 valid samples (42% on 11th, 30% on 12th, 28% on 13th) from Beijing, Shanghai, Hubei, Guangdong, Zhejiang, Jiangsu, Hebei and Shaanxi. Table 2 reports the demographics of the samples. About 43.85% of the survey respondents were female. 34.27% of the respondents were over than 35 years old. 141 respondents claimed there were COVID-19 cases in their communities, 40 from Hubei province, 52 from Guangdong province, 19 from Hebei province, 8 from Jiangsu province, 7 from Zhejiang province, 6 from Shaanxi province, 5 from Beijing, and 4 from Shanghai.
Table 2

Descriptive statistics.

Sample VariablePooled sample (N = 1188)Willing to get vaccinatedWTP
Gender:   
Male56.15%78.42%129.92
Female43.85%80.20%131.14
Age:   
≤ 24 years old21.46%83.64%139.95
25–34 years old44.28%81.67%147.58
35–44 years old22.56%78.65%117.42
45–54 years old9.18%63.56%112.67
≥55 years old2.53%68.75%111.93
Education level:   
≤ 12 years21.92%76.98%125.47
> 12 years78.08%80.10%138.63
Personal monthly income:   
< 2000 yuan14.73%76.56%127.72
2000–3999 yuan14.23%80.66%127.23
4000–5999 yuan21.21%76.92%121.13
6000–7999 yuan15.91%80.40%140.78
8000–9999 yuan13.72%84.80%144.14
10,000–14,999 yuan14.14%80.68%154.84
≥ 15,000 yuan6.06%75.00%150.66
Children under 12 years old:   
No42.67%74.49%127.47
Yes57.33%83.08%132.67
Total100%79.41%%130.45
Table 2 reports the statistics of respondents’ willingness to get vaccinated. The average rate of willingness to get a vaccine is 79.41%, while 87.96% of the respondents in Hubei province report they are willing to get a vaccine against COVID-19. If the vaccine is effective and can ensure immunity, mass vaccination may help achieve herd immunity according experts’ estimation [7]. Interestingly, respondents in Beijing and Shanghai are least willing to get vaccinated (73.24% and 65.63%, respectively), which is not consistent with the general view that income is positively associated with the demand for vaccines [27]. There is a significant difference in the rate of willingness to get vaccinated among different age groups. Based on currently available information and clinical expertise, older adults and people of any age who have serious underlying medical conditions might be at higher risk of developing severe illnesses from COVID-19. However, the rate of willingness to get vaccinated is low in the elderly group.

Willingness to pay for vaccines against COVID-19

Fig 2 reports the statistics of respondents’ willingness to pay for a COVID-19 vaccine shot. The average amount that respondents are willing to pay for a vaccine is 130.45 yuan (the WTP value for the up-open interval is equal to the sum of the lower boundary and the half distance of the neighboring interval). Compared to the price of a flu vaccine, 50% of the respondents pay an amount of less than 100 yuan for a vaccine shot. This may be because the number of COVID-19 cases continues to fall in China during March 2020.
Fig 2

The frequency of WTP for a COVID-19 vaccine shot.

Who are willing to get a COVID-19 vaccine

Using a binary logit regression model, we identify variables that have a statistically significant association with the probability of willingness to get a vaccine. The dependent variable willingness to get vaccinated equals 1 if the respondent is willing to get vaccinated and 0 if not. Table 3 reports the regression results.
Table 3

Regression results.

VariablesWillingness to get vaccinatedWTP for a vaccine shot
 Coef.Odds RatioCoef.
Female-0.1630.8490.605
 -0.262 -0.906
Age (≤ 24 years old)0.615**1.859.242
 -0.017 -0.269
Age (35–44 years old)-0.313*0.732-28.96***
 -0.099 0
Age (45–54 years old)-0.752***0.472-32.75***
 -0.001 -0.001
Age (≥55 years old)-0.6060.545-27.59
 -0.137 -0.112
Educational level-0.0110.989-3.895
 -0.953 -0.561
Income (2000–3999 yuan)0.620**1.85912.76
 -0.03 -0.202
Income (4000–5999 yuan)0.4151.5146.849
 -0.134 -0.496
Income (6000–7999 yuan)0.544*1.72326.29**
 -0.07 -0.014
Income (8000–9999 yuan)0.862***2.36933.55***
 -0.01 -0.003
Income (10,000–14,999 yuan)0.4951.6443.05***
 -0.127 0
Income (≥ 15,000 yuan)0.2411.27239.00***
 -0.523 -0.006
Children under 12 years old0.552***1.737-1.723
 0 -0.761
AIC1,269.904,689.20
BIC1,341.904,763
Results show that age is associated with the willingness to get vaccinated. Taking those from 25–34 years of age as a baseline, younger respondents are more likely to be willing to get a vaccine against COVID-19. However, respondents from 35–44 years and 45–54 years of age are less willing to be vaccinated, even though the COVID-19 guidance claims that older adults seem to be at higher risk of developing more serious complications from COVID-19 illness. Also, those having a high personal monthly income (8000–9999 yuan) are generally more willing to get vaccines, compared to the respondents with low incomes. Some personal monthly income variables are positive but not significant. Besides, respondents that have children under 12 years old are more willing to get vaccinated. Furthermore, we use an interval regression model to study the hypothetical WTP for vaccination. The dependent variable is the interval of WTP. As expected, WTP for vaccination is positively associated with income. The elderly are not willing to pay as much for a COVID-19 vaccine shot. The families with children are less willingness to make a payment than others, because most vaccines are free for children in China.

Conclusions and discussion

COVID-19 (coronavirus disease 2019), an ongoing global pandemic, is the most extensive to afflict humanity in a century. Although no COVID-19 vaccine has been accomplished, the Phase 3 clinical trial published earlier in the fourth week of July 2020 is very encouraging and promising [28]. Designing an effective vaccination strategy demands the identification of consumers’ willingness to get vaccinated and their willingness to pay for a COVID-19 vaccine. This paper provides important information for policy makers to help them make an effective vaccination strategy. Firstly, this study shows that the proportion of those willing to get vaccinated in China is 79.41%, which is quite higher than that in France and the U.S. It means vaccination coverage in different countries is quite divergent. Secondly, although the average amount respondents are willing to pay for vaccines in China is 130.45 yuan, more than half of respondents are not willing to pay more than 100 yuan for a COVID-19 vaccine shot. The regression results also show that income also matters. Excessively high price of the COVID-19 vaccine may deter a substantial share of the at-risk people with low incomes from getting vaccinated. Partial subsidies would be needed to raise the vaccination rate. Thirdly, although the COVID-19 guidance claims that older adults seem to be at higher risk than the young, they are less willing to get vaccinated, and are not willing to pay as much for a COVID-19 vaccine shot. Although our samples were from several representative provinces/cities, randomly selected from a huge sample database (with 2.6 million samples), it may not be an accurate representation of China’s population. This is because the people with a low educational level and the elderly are less likely to response to the online survey. To draw a more robust conclusion, future research can conduct similar studies covering more provinces of China, especially the rural areas. Future studies can also analyze the impacts of population density, trust in government and risk perception on consumers’ willingness to get vaccinated. (XLSX) Click here for additional data file.
  7 in total

1.  The demand for a dengue vaccine: a contingent valuation survey in Metro Manila.

Authors:  Rosalina Palanca-Tan
Journal:  Vaccine       Date:  2007-12-31       Impact factor: 3.641

2.  Perceptions matter: beliefs about influenza vaccine and vaccination behavior among elderly white, black and Hispanic Americans.

Authors:  Karen G Wooten; Pascale M Wortley; James A Singleton; Gary L Euler
Journal:  Vaccine       Date:  2012-08-30       Impact factor: 3.641

3.  Consumer food stockpiling behavior and willingness to pay for food reserves in COVID-19.

Authors:  Erpeng Wang; Ning An; Zhifeng Gao; Emmanuel Kiprop; Xianhui Geng
Journal:  Food Secur       Date:  2020-08-06       Impact factor: 3.304

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  The Willingness to Pay for Vaccination against Tick-Borne Encephalitis and Implications for Public Health Policy: Evidence from Sweden.

Authors:  Daniel Slunge
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

6.  The landscape of vaccines in China: history, classification, supply, and price.

Authors:  Yaming Zheng; Lance Rodewald; Juan Yang; Ying Qin; Mingfan Pang; Luzhao Feng; Hongjie Yu
Journal:  BMC Infect Dis       Date:  2018-10-04       Impact factor: 3.090

  7 in total
  6 in total

1.  COVID-19 vaccination hesitancy and associated factors among solid organ transplant recipients in China.

Authors:  Tingting Chen; Xiaoyu Li; Qiuting Li; Lihong Huang; Qingqing Cai; Yuzhu Wang; Ying Jiang; Qing Xu; Qianzhou Lv; Jina Wang
Journal:  Hum Vaccin Immunother       Date:  2021-09-29       Impact factor: 4.526

Review 2.  Factors Associated with COVID-19 Vaccine Hesitancy among Visible Minority Groups from a Global Context: A Scoping Review.

Authors:  Candy Ochieng; Sabrita Anand; George Mutwiri; Michael Szafron; Khrisha Alphonsus
Journal:  Vaccines (Basel)       Date:  2021-12-07

3.  Systematic Review and Meta-Analysis of COVID-19 Vaccination Acceptance.

Authors:  Mohd Noor Norhayati; Ruhana Che Yusof; Yacob Mohd Azman
Journal:  Front Med (Lausanne)       Date:  2022-01-27

4.  Willingness to pay for COVID-19 vaccines in Jordan: Applying the health belief model.

Authors:  Rasha M Arabyat; Mohammad B Nusair; Sayer I Al-Azzam; Haneen A Amawi; Feras Darwish El-Hajji
Journal:  Res Social Adm Pharm       Date:  2022-09-13

5.  The main decision-making competence for willingness-to-pay towards COVID-19 vaccination: a family-based study in Taizhou, China.

Authors:  Chengwen Luo; Mei-Xian Zhang; Eva Jiang; Mindan Jin; Tao-Hsin Tung; Jian-Sheng Zhu
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

6.  Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China.

Authors:  Hui Jun Zhou; Lei Pan; Hui Shi; Ji Wei Luo; Pei Wang; Hannah K Porter; Ye Bi; Minghui Li
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.